Regorafenib shows significant survival gains in refractory liver cancer

Posted by on June 30, 2016 5:59 pm
Categories: health

Oral multikinase inhibitor regorafenib achieves significantly improved survival rates compared to placebo in patients with hepatocellular carcinoma, according to data from the phase III RESORCE trial.

Leave a Reply

Your email address will not be published. Required fields are marked *